Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Opthea initiates OPT-302 Diabetic Macular Edema clinical trial

Published 01/03/2018, 07:30 AM
© Reuters.  Opthea initiates OPT-302 Diabetic Macular Edema clinical trial
  • Opthea Limited (OTCPK:CKDXY) has commenced a Phase 1b/2a trial evaluating the safety and efficacy of OPT-302 in patients with center-involved diabetic macular edema (DME).
  • This multi-centre clinical trial enrolling ~117 patients is a two-part design consisting of a Phase 1b dose escalation of OPT-302 in combination with the VEGF-A inhibitor Eylea, followed by a Phase 2a dose expansion with treatment allocated in a 2:1 ratio to either OPT-302 with Eylea, or Eylea monotherapy.
  • The primary objectives are to evaluate the safety/tolerability and efficacy by determining clinical response rate. Results are anticipated in H1 2019.
  • OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 or ‘Trap’ molecule that blocks the activity of two proteins (VEGF-C and VEGF-D) that cause blood vessels to grow and leak.
  • Now read: Regeneron Regrets: Why Our Higher-Risk Portfolio Underperformed


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.